Actively Enrolling Dry AMD Clinical Trials
Dry AMD & Advanced Dry AMD (Geographic Atrophy)
Dry age-related macular degeneration (AMD) is prevalent among patients over 60 years old. It is characterized by the accumulation of small deposits, akin to cholesterol, beneath the macula. While these deposits are generally benign, a subset of patients with dry AMD progresses to an advanced stage known as geographic atrophy (GA). In GA, the tissue directly beneath the retina (retinal pigment epithelium) begins to deteriorate, resulting in dense blind spots that gradually expand over time.
For affected patients, everyday tasks become formidable challenges. Reading, driving, and even recognizing familiar faces can become increasingly difficult. However, ongoing research sheds light on the disease process, and numerous molecules are under evaluation to slow down vision loss in these patients. Treatment options include painless eye injections, systemic subcutaneous injections, and cutting-edge gene therapy.
Our unwavering commitment is to help develop effective treatments that prevent blindness in our patients. We persistently explore innovative avenues, leaving no stone unturned in our pursuit of better vision outcomes.
JOURNEY
Perceive Biotherapeutics (South San Francisco, CA)
This is a prospective, open-label, multi-center Phase 1/2a study to evaluate the safety of a single, unilateral intravitreal (IVT) injection of escalating dose levels of VOY-101 therapy in subjects with advanced non-neovascular age-related macular degeneration (AMD).
PI: Nikolas JS London, MD, FACS
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: Perceive Biotherapeutics
Contact: [email protected]
GALLOP
Apellis (Waltham, MA)
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration.
PI: Thomas Lazzarini, MD
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: Apellis
Contact: [email protected]
SURF
ADARx Pharmaceuticals (San Diego, CA)
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
PI: Nikolas JS London, MD, FACS
Status: Active and enrolling
NIH registration: Clinicaltrials.gov
Sponsor website: ADARx Pharmaceuticals
Contact: [email protected]
Years in Practice in San Diego
We've been leading the way in retinal care and clinical research since 1979.